Fang C, Lee KK, Nietupski R, et al. Discovery of heterocyclic replacements for the coumarin core of anti-tubercular FadD32 inhibitors. Bioorg Med Chem Lett. 2018;28(22):3529-3533. doi:10.1016/j.bmcl.2018.09.037.
Nakasone MA, Lewis TA, Walker O, et al. Structural Basis for the Inhibitory Effects of Ubistatins in the Ubiquitin-Proteasome Pathway. Structure. 2017;25(12):1839-1855.e11. doi:10.1016/j.str.2017.10.007.
Mukherjee A, Gagnon D, Wirth DF, Richard D. Inactivation of Plasmepsins 2 and 3 Sensitizes Plasmodium falciparum to the Antimalarial Drug Piperaquine. Antimicrob Agents Chemother. 2018;62(4). doi:10.1128/AAC.02309-17.
Bopp S, Magistrado P, Wong W, et al. Plasmepsin II-III copy number accounts for bimodal piperaquine resistance among Cambodian Plasmodium falciparum. Nat Commun. 2018;9(1):1769. doi:10.1038/s41467-018-04104-z.
Yang J, Shamji A, Matchacheep S, Schreiber SL. Identification of a small-molecule inhibitor of class Ia PI3Ks with cell-based screening. Chem Biol. 2007;14(4):371-7. doi:10.1016/j.chembiol.2007.02.004.
Sundberg TB, Choi HG, Song J-H, et al. Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells. Proc Natl Acad Sci U S A. 2014;111(34):12468-73. doi:10.1073/pnas.1412308111.
Youngsaye W, Vincent B, Hartland CL, et al. Piperazinyl quinolines as chemosensitizers to increase fluconazole susceptibility of Candida albicans clinical isolates. Bioorg Med Chem Lett. 2011;21(18):5502-5. doi:10.1016/j.bmcl.2011.06.105.
Palomo V, Perez DI, Roca C, et al. Subtly Modulating Glycogen Synthase Kinase 3 β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases. J Med Chem. 2017;60(12):4983-5001. doi:10.1021/acs.jmedchem.7b00395.
Cash BM, Prevost N, Wagner FF, Comins DL. Studies toward the total synthesis of dihydrolycolucine. Preparation of AB and CEF ring fragments. J Org Chem. 2014;79(12):5740-5. doi:10.1021/jo500878v.